Target hit in rare heart condition could raise eyebrows at Bristol Myers

20 July 2021

Results from muscle biology specialist Cytokinetics (Nasdaq: CYTK) could present a challenge to Bristol Myers Squibb’s (NYSE: BMY) recently-bought mavacamten program.

The company is testing omecamtiv mecarbil, a selective cardiac myosin activator, with funding and strategic backing from French drugmaker Servier.

The program was also partnered with Amgen (Nasdaq: AMGN), until a Phase III failure at the end of 2020 caused the Californian firm to terminate its agreement.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK